Basilea Pharmaceutica (0QNA) Ratios
Basilea Pharmaceutica Ratios
GB:0QNA's free cash flow for Q2 2026 was $18.56M. For the 2026 fiscal year, GB:0QNA's free cash flow was decreased by $-409.00K and operating cash flow was $18.97M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 5.11 | 4.85 | 3.20 | 2.34 | 1.38 |
| Quick Ratio | 4.68 | 4.16 | 2.64 | 2.02 | 1.25 |
| Cash Ratio | 0.60 | 2.65 | 1.26 | 0.49 | 0.32 |
| Solvency Ratio | 0.27 | 0.45 | 0.07 | 0.06 | -0.01 |
| Operating Cash Flow Ratio | 1.26 | 1.63 | 0.30 | 0.09 | -0.18 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 36.06 | 0.92 | 0.19 | -0.26 |
| Net Current Asset Value | $ 97.67M | $ 44.15M | $ -31.15M | $ -66.20M | $ -64.81M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.32 | 0.43 | 0.74 | 0.85 | 0.89 |
| Debt-to-Equity Ratio | 0.70 | 1.38 | -12.86 | -9.03 | -3.74 |
| Debt-to-Capital Ratio | 0.41 | 0.58 | 1.08 | 1.12 | 1.37 |
| Long-Term Debt-to-Capital Ratio | 0.37 | 0.54 | 1.12 | 1.19 | 2.63 |
| Financial Leverage Ratio | 2.20 | 3.18 | -17.32 | -10.66 | -4.22 |
| Debt Service Coverage Ratio | 14.24 | 12.56 | 0.87 | 0.55 | 0.05 |
| Interest Coverage Ratio | 15.37 | 14.08 | 1.71 | 1.88 | 0.15 |
| Debt to Market Cap | 0.11 | 0.20 | 0.26 | 0.31 | 0.46 |
| Interest Debt Per Share | 7.58 | 9.60 | 11.66 | 16.61 | 19.44 |
| Net Debt to EBITDA | 1.12 | -0.14 | 2.96 | 5.74 | 24.39 |
| Profitability Margins | |||||
| Gross Profit Margin | 83.09% | 81.45% | 83.00% | 81.86% | 83.75% |
| EBIT Margin | 22.20% | 29.59% | 13.74% | 15.64% | 2.88% |
| EBITDA Margin | 22.98% | 30.27% | 14.71% | 17.74% | 4.54% |
| Operating Profit Margin | 22.20% | 29.34% | 12.18% | 12.55% | 0.80% |
| Pretax Profit Margin | 19.75% | 28.90% | 6.64% | 8.19% | -4.59% |
| Net Profit Margin | 17.30% | 37.21% | 6.63% | 8.22% | -4.61% |
| Continuous Operations Profit Margin | 17.34% | 37.21% | 6.63% | 8.22% | -4.61% |
| Net Income Per EBT | 87.58% | 128.76% | 99.90% | 100.37% | 100.54% |
| EBT Per EBIT | 88.95% | 98.50% | 54.47% | 65.26% | -572.37% |
| Return on Assets (ROA) | 14.26% | 30.10% | 6.03% | 5.50% | -2.76% |
| Return on Equity (ROE) | 31.42% | 95.80% | -104.48% | -58.64% | 11.66% |
| Return on Capital Employed (ROCE) | 22.17% | 28.83% | 15.28% | 12.70% | 1.63% |
| Return on Invested Capital (ROIC) | 19.29% | 28.28% | 13.40% | 10.00% | 0.60% |
| Return on Tangible Assets | 14.27% | 30.15% | 6.05% | 5.51% | -2.77% |
| Earnings Yield | 6.01% | 15.52% | 2.47% | 2.24% | -1.43% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.67 | 3.69 | 5.65 | 2.39 | 2.30 |
| Payables Turnover | 2.61 | 3.37 | 4.58 | 140.33 | 2.27 |
| Inventory Turnover | 1.82 | 1.22 | 1.01 | 1.11 | 1.06 |
| Fixed Asset Turnover | 12.80 | 10.98 | 7.67 | 6.85 | 50.67 |
| Asset Turnover | 0.82 | 0.81 | 0.91 | 0.67 | 0.60 |
| Working Capital Turnover Ratio | 1.23 | 1.49 | 1.54 | 1.77 | 1.23 |
| Cash Conversion Cycle | 159.76 | 288.90 | 344.70 | 479.97 | 343.28 |
| Days of Sales Outstanding | 99.39 | 99.02 | 64.58 | 152.42 | 158.81 |
| Days of Inventory Outstanding | 200.22 | 298.27 | 359.77 | 330.15 | 345.46 |
| Days of Payables Outstanding | 139.85 | 108.39 | 79.65 | 2.60 | 160.98 |
| Operating Cycle | 299.61 | 397.29 | 424.35 | 482.57 | 504.26 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 5.08 | 6.15 | 1.19 | 0.59 | -2.74 |
| Free Cash Flow Per Share | 4.85 | 6.01 | 1.10 | 0.32 | -2.81 |
| Dividend Paid and CapEx Coverage Ratio | 21.69 | 43.49 | 13.78 | 2.14 | -37.23 |
| Capital Expenditure Coverage Ratio | 21.69 | 43.49 | 13.78 | 2.14 | -37.23 |
| Operating Cash Flow Coverage Ratio | 0.70 | 0.67 | 0.11 | 0.04 | -0.15 |
| Operating Cash Flow to Sales Ratio | 0.27 | 0.36 | 0.09 | 0.05 | -0.22 |
| Free Cash Flow Yield | 8.86% | 14.53% | 3.12% | 0.69% | -6.88% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 16.63 | 6.44 | 40.50 | 44.72 | -69.98 |
| Price-to-Sales (P/S) Ratio | 2.88 | 2.40 | 2.69 | 3.68 | 3.23 |
| Price-to-Book (P/B) Ratio | 5.22 | 6.17 | -42.32 | -26.22 | -8.16 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 11.28 | 6.88 | 32.04 | 144.75 | -14.54 |
| Price-to-Operating Cash Flow Ratio | 10.76 | 6.72 | 29.72 | 76.99 | -14.93 |
| Price-to-Earnings Growth (PEG) Ratio | -0.34 | 0.01 | -2.75 | -0.16 | 1.18 |
| Enterprise Value Multiple | 13.63 | 7.78 | 21.22 | 26.47 | 95.50 |
| Enterprise Value | 727.96M | 490.88M | 492.00M | 693.80M | 642.03M |
| EV to EBITDA | 13.63 | 7.78 | 21.22 | 26.47 | 95.50 |
| EV to Sales | 3.13 | 2.35 | 3.12 | 4.70 | 4.33 |
| EV to Free Cash Flow | 12.29 | 6.76 | 37.24 | 184.87 | -19.53 |
| EV to Operating Cash Flow | 11.72 | 6.60 | 34.54 | 98.33 | -20.05 |
| Tangible Book Value Per Share | 10.44 | 6.67 | -0.88 | -1.80 | -5.07 |
| Shareholders’ Equity Per Share | 10.47 | 6.70 | -0.83 | -1.75 | -5.02 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.12 | -0.29 | 0.00 | -0.00 | -0.01 |
| Revenue Per Share | 19.02 | 17.25 | 13.15 | 12.46 | 12.68 |
| Net Income Per Share | 3.29 | 6.42 | 0.87 | 1.02 | -0.58 |
| Tax Burden | 0.88 | 1.29 | 1.00 | 1.00 | 1.01 |
| Interest Burden | 0.89 | 0.98 | 0.48 | 0.52 | -1.59 |
| Research & Development to Revenue | 0.46 | 0.37 | 0.49 | 0.50 | 0.63 |
| SG&A to Revenue | 0.15 | 0.15 | 0.21 | 0.21 | 0.20 |
| Stock-Based Compensation to Revenue | 0.02 | 0.02 | 0.03 | 0.02 | 0.03 |
| Income Quality | 1.54 | 0.96 | 1.36 | 0.58 | 4.69 |
Currency in CHF
